BPC-157

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a gastric protein, run primarily for tissue and tendon healing and GI repair. Community users cluster tightly around 250–500 mcg subcutaneously in the morning, in 4–8 week cycles — notably weight-independent, with similar effective doses reported across a wide range of body weights; clinicians tend to anchor at 500 mcg on a 5-days-on / 2-days-off schedule. The catch: there are no published human RCTs — every protocol in circulation, clinician or otherwise, extrapolates from animal data.

BPC-157

Research Evidence

Evidence shape

BPC-157 sits at the lowest tier of clinical evidence: one registered trial, for hamstring muscle strain, is still recruiting and has posted no results. The remainder of the evidence base is preclinical — animal models and mechanistic work — with no completed blinded human study against any indication. The gap between its broad community use and what the registered trial record can support is wide.

Depthhow much
1 registered trial
1 recruiting / active
Breadthhow many areas
2 indications mapped
1 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
Breadth and depth16 rows captured
Human
direct clinical signal
1
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
Natty Peptides
UK
2400 mg
$34.30
$0.013/mg
2
Alpha Omega Peptide
US
500 mg
$170.00
$0.34/mg
3
Ascension Peptides
US
100 mg
$53.00
$0.53/mg
4
High Purity Peptides
HK
100 mg
$60.00
$0.6/mg
5
Purerxpeptides
US
25 mg
$23.00
$0.92/mg
6
Amino Lair
unknown
50 mg
$46.60
$0.932/mg

price offers can be sorted by column

1-6 of 162

Dosing & Protocol

How BPC-157 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 1
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

1 completed trial identified; trial dosing not reliably extracted from registry data.

Clinician practice
Doctor & published-protocol guidance · n = 2
Typical dose
10 µg
10 µg
10 µg
Frequency
BID
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 10 µg BID subQ (2 sources).

2 sources
Anecdotal
Community-reported real-world use · n = 58
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports show high positive efficacy for injury recovery (81.6% positive in 38 reports), gut healing (78.6% positive in 14 reports), and joint health (83.3% positive in 6 reports). Specific dose hints from these posts were not broadly aggregated.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for BPC-157, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.